China Proposes Changes for Clinical Trials Practices and Regulations

Clinical Trials Advisor
A A
China’s Food and Drug Administration recently proposed revisions to its good clinical practices guidelines, standardizing the conduct of drug studies. According to the global law firm Ropes & Gray, the revisions are similar to those proposed by the International Conference on Harmonization guidelines.

To View This Article:

Login

Subscribe To Clinical Trials Advisor